Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
Nodal Metastasis in Vermillion, Cutaneous, and Mucosal Lip Squamous Cell Carcinoma: Examining Vermillion Invasion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gardner James R, Nguyen Kenny, Herberger Lindsey, Zaniletti Isabella, Eckard Peter, Phillips-Cosio Robert, Saadi Carissa, Moreno Mauricio, Vural Emre, Sunde Jumin
Аннотация
OBJECTIVE: To compare oncologic outcomes among vermillion, nonvermillion cutaneous, and mucosal lip squamous cell carcinoma (SCCa), with a focus on the prognostic significance of vermillion SCCa.
STUDY DESIGN: Retrospective cohort study.
SETTING: Tertiary academic medical center.
METHODS: This retrospective cohort study included all patients diagnosed with SCCa of the mucosal, nonvermillion, or vermillion lip between 2013 and 2024 at our tertiary institution. Subsites were compared in terms of categorical variables using Fisher's exact or χ2 tests, and continuous variables with Kruskal-Wallis test. Covariate-adjusted Cox proportional hazards regression was used to estimate the relative hazard of mortality by subsite.
RESULTS: Two hundred and ninety-three patients were identified. Subsites included 44.0% vermillion, 38.9% nonvermillion, and 17.1% mucosal lip. Mucosal tumors were more often stage II or higher (58.0%) than nonvermillion (8.7%) or vermillion (22.5%). In pairwise comparisons, nodal metastasis rates were significantly higher for mucosal (24%) and vermillion (14%) than nonvermillion (0) (P < .001). Nonvermillion and vermillion SCCa showed significant lower hazard than mucosal SCCa (HR 0.32, 95% CI 0.16-0.66, P = .002, and HR 0.31, 95% CI 0.15-0.63, P = .001, respectively), though this difference no longer persisted after covariate-adjustment. Recurrence rates did not differ following treatment (P = .291). Mucosal SCCa had worse disease-specific mortality (20.5%) than vermillion (2.6%) or non-vermillion SCCa (0) (P < .001).
CONCLUSION: Vermillion and mucosal lip SCCa show higher nodal involvement than nonvermillion SCCa. Mucosal SCCa demonstrates worse survival in unadjusted analysis, prior to covariate-adjustment. Larger studies are needed to validate the adjusted association and clarify long-term prognostic implications.
STUDY DESIGN: Retrospective cohort study.
SETTING: Tertiary academic medical center.
METHODS: This retrospective cohort study included all patients diagnosed with SCCa of the mucosal, nonvermillion, or vermillion lip between 2013 and 2024 at our tertiary institution. Subsites were compared in terms of categorical variables using Fisher's exact or χ2 tests, and continuous variables with Kruskal-Wallis test. Covariate-adjusted Cox proportional hazards regression was used to estimate the relative hazard of mortality by subsite.
RESULTS: Two hundred and ninety-three patients were identified. Subsites included 44.0% vermillion, 38.9% nonvermillion, and 17.1% mucosal lip. Mucosal tumors were more often stage II or higher (58.0%) than nonvermillion (8.7%) or vermillion (22.5%). In pairwise comparisons, nodal metastasis rates were significantly higher for mucosal (24%) and vermillion (14%) than nonvermillion (0) (P < .001). Nonvermillion and vermillion SCCa showed significant lower hazard than mucosal SCCa (HR 0.32, 95% CI 0.16-0.66, P = .002, and HR 0.31, 95% CI 0.15-0.63, P = .001, respectively), though this difference no longer persisted after covariate-adjustment. Recurrence rates did not differ following treatment (P = .291). Mucosal SCCa had worse disease-specific mortality (20.5%) than vermillion (2.6%) or non-vermillion SCCa (0) (P < .001).
CONCLUSION: Vermillion and mucosal lip SCCa show higher nodal involvement than nonvermillion SCCa. Mucosal SCCa demonstrates worse survival in unadjusted analysis, prior to covariate-adjustment. Larger studies are needed to validate the adjusted association and clarify long-term prognostic implications.